Additional Information About the Proposed Merger Between Opexa Therapeutics, Inc. and Acer Therapeutics Inc. and Where to Find It. In connection with the proposed merger, Opexa has filed a registration statement on Form S-4 with the Securities and Exchange Commission (the "SEC"), including a proxy statement / prospectus / information statement. Opexa Therapeutics, Inc. 2635 Technology Forest Blvd. The Woodlands, TX 77381 (281) 272-9331 Opexa is a biopharmaceutical company that has historically focused on developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis, or MS, as well as other autoimmune diseases such as neuromyelitis Multiple Sclerosis Market 2020-2027 Research Analysis by Top Companies Actelion Pharmaceuticals Ltd, GlaxoSmithKline plc., Opexa Therapeutics, Inc Published: April 10, 2020 at 3:40 p.m. ET Comments About Acer Therapeutics Acer, headquartered in Newton, MA, is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Opexa Therapeutics has a beta of 2.11, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts. A high level of beta means investors face higher risk associated with potential gains and losses driven by market movements.Based on this beta value,OPXA can help magnify your
Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company's product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United
Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis (MS) and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product is Tovaxin, a T-cell therapy for MS which is in Phase IIb trials. Opexa Therapeutics to merge with Acer Therapeutics. In a regulatory filing, Opexa Therapeutics disclosed that the company and Acer Therapeutics have entered into an agreement and plan of merger and reorganization under which, at the closing of the merger, each outstanding share of Acer common stock will be converted into the right to receive approximately one share of common stock of Opexa Is Opexa Therapeutics Stock on Sale? Based on our analysis, we believe that you should not buy Opexa Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution. Real-time trade and investing ideas on Opexa Therapeutics, Inc. OPXAW from the largest community of traders and investors.
Get detailed financial information for the Opexa Therapeutics, Inc. (OPXA:) stock quote. View graphs, news, comments, and more.
----- opexa therapeutics, inc. (ACER) REPORT OVERVIEW Opexa Therapeutics' Recent Financial Performance Opexa Therapeutics is expected to report earnings on August 13th, 2018. The report will be Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase Opexa Therapeutics, Inc. today announced the completion of patient enrollment in a 150-patient Phase IIb safety and efficacy study (TERMS). THE WOODLANDS, TX, USA | May 17, 2007 | Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced the completion of patient enrollment in a 150-patient Phase IIb safety and Opexa Therapeutics公司(NASDAQ： OPXA)今天宣布重新修订了与德国达姆施塔特的默克公司的分公司默克雪兰诺(Merck Serono)的授权许可协议并将收到对方支付的3百万美金里程金。 该笔资金将为公司在研的治疗继发性进展性多发性硬化症（SPMS：Secondary Progressive Multiple Sclerosis)的个性化免疫治疗药物Tcelna Neil Warma took the reins as Opexa Therapeutics Inc's (NASDAQ:OPXA) CEO in 2008 and earned a total compensation of $618,471 over the past year.We're going to find out whether Warma's stock-based compensation is in-line with the salaries of CEO-peers in globally recognized companies.
编译/张季蕾. Opexa Therapeutics公司是一个为包括多发性硬化（MS）和视神经脊髓炎（NMO）在内的自身免疫病研发个体性的免疫疗法的生物制药公司，该公司宣布，基于一些之前已经指定阶段研究的完成，该公司已经和一位私人投资者达成了费用高达5,000,000美元的购买协议，成立该公司的NMO项目，包括
Opexa Therapeutics Inc(usopxa)股吧，股民朋友可以在这里畅所欲言，分析讨论股票名的最新动态。东方财富股吧，专业的股票论坛社区。 OPEXA THERAPEUTICS INC (NASDAQ:OPXA) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share OPEXA THERAPEUTICS INC | Nasdaq: OPXA | Nasdaq Real time Opexa Therapeutics (OPXA) stock price quote, stock graph, news & analysis. Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. The requested symbol was not found in our database. Try searching for some other symbol on Yahoo Finance
Opexa Therapeutics Price: This is the Price-site for the company Opexa Therapeutics on Markets Insider
Opexa Therapeutics Price: This is the Price-site for the company Opexa Therapeutics on Markets Insider Opexa Therapeutics公司(NASDAQ： OPXA)今天宣布重新修订了与德国达姆施塔特的默克公司的分公司默克雪兰诺(Merck Serono)的授权许可协议并将收到对方支付的3百万美金里程金 OPEXA THERAPEUTICS, INC. (NASDAQ:OPXA) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition. On August 14, 2017, Opexa Therapeutics Opexa Therapeutics, Inc.ACER has been struggling lately, but the selling pressure may be coming to an end soon. That is because ACER recently saw a Hammer Chart Pattern which can signal that the Investors in Opexa Therapeutics were crushed on Friday, with the stock tumbling more than 69% on enormous volume, settling at $1.05 a share, a level not seen since the company implemented a 1:8